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Background/aim: The aim of this study is to evaluate the effect of biologic drugs on the tuberculin skin test in patients with juvenile
idiopathic arthritis.
Materials and methods: A total of 234 biologic drug-using juvenile idiopathic arthritis patients and 45 healthy controls were enrolled
in the study. The tuberculin skin test results of the patients, which had been routinely provided during follow-up, were obtained from
the patient files. Tuberculin skin test values of ≥5 mm were considered to be positive.
Results: The mean diameter of tuberculin skin test induration was 4.99 ± 6.84 mm (IQR: 0–10 mm) and 7.83 ± 3.47 mm (IQR: 0–16
mm) in patients and controls, respectively (P < 0.05). Tuberculin skin test positivity (≥5 mm) was found in 96 (41%) and 38 (84.4%)
of patients and controls, respectively (P < 0.001). There was no induration in 125 (53.4%) patients and 3 (6.6%) healthy controls,
respectively (P < 0.001).
Conclusion: In the patients with juvenile idiopathic arthritis who were using biologic drugs, tuberculin skin test induration was
significantly lower compared to the control group. Tuberculin skin tests alone seem inadequate for recognition of latent tuberculosis in
juvenile idiopathic arthritis patients on anti-TNF therapy.
Key words: Juvenile idiopathic arthritis, tuberculin test, biologic therapy

1. Introduction
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children that presents with
peripheral arthritis. The pathogenesis of the disease is
unknown, although it is thought to be triggered by factors
such as stress, infections, autoimmunity, trauma, and
genetic tendency (1).
Patients with inflammatory diseases such as JIA are
more prone to severe systemic or localized infections. This
increased risk is due to a combination of dysfunctional
immune system and secondary immune deficiency as a
consequence of immunosuppressive drugs. Tuberculosis
(TB) is one of the serious infections, especially in
developing countries. A latent form of this disease
could be detected by the tuberculin skin test (TST) (2).
Factors that can facilitate the development of TB are
increased autoimmunity leading to immune dysfunction,
immunosuppressive agents, Bacillus Calmette–Guérin

(BCG) vaccination status, previous TB infection, and
the burden of TB disease in the community (3). TB has
varying degrees of clinical phenotypes, ranging from
asymptomatic cases to severe disseminated infection.
After the primary infection has been acquired, the disease
course differs.
Latent TB infection is a condition in which a child is
infected with Mycobacterium tuberculosis bacteria but
does not have apparent clinical or radiological signs of
the disease. Patients with latent TB do not transmit the
infection to others. However, they are at risk of developing
an active and contagious infection in the case of immune
system dysfunction (4).
The TST or purified protein derivative (PPD) test
causes a delayed hypersensitivity reaction mediated by Th1
cells and monocytes/macrophages. It shows the person’s
previous exposure to the TB bacilli but does not give
precise information of TB disease (5,6). The BCG vaccine
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may show cross-reactivity to the TST, but the reaction is
usually smaller than 10 mm and gradually decreases. TST
positivity is seen in 0%–18% of people vaccinated with BCG
during infancy. Indurations larger than 10 mm are unlikely
in the case of previous BCG vaccination. It was reported
that there is a direct relationship between number of BCG
vaccinations and TST reaction size (7). Tuberculin skin
tests in biologic-naive JIA patients were assessed for the first
time in a study conducted previously by our group (8). We
found that neither the activity nor subtype of the disease
or the use of corticosteroids and methotrexate affected the
TST response. The results of the study showed that even the
smaller indurations of TST should be considered as positive
when screening JIA patients for latent TB (8). Another study
from Turkey also confirmed the mentioned findings; TST
response was smaller in JIA patients compared to healthy
controls (9). The aim of the present study was to evaluate
the effect of biological drugs on TST, which was not studied
in our previous study.
2. Materials and methods
2.1. Study groups
We retrospectively evaluated the patient files of our 234
JIA patients (102 males, 132 females) who were on biologic
therapy for at least 6 months. All the JIA patients were
diagnosed and classified into subgroups according to the
International League of Associations for Rheumatology
criteria (10). All the data regarding age, sex, duration of
disease, treatment options, and duration of therapy were
recorded from patient files. The induration results of TST
after the first 6 months of anti-TNF therapy were taken in
a retrospective scope from patient records. Presence of any
family member with TB and close contact with patients with
infectious TB were noted. The subjects that had received
INH prophylaxis were also recorded. TST induration results
of 45 healthy children (23 males, 22 females) were obtained
from a study previously performed by our group (8).
2.2. Tuberculin skin test
The TST is performed by an intradermal injection of
0.1 mL of PPD into the volar surface of the forearm.
Hyperemia and induration occur at the site of injection
after 2 to 3 days if the patient has been vaccinated with
BCG or infected with TB bacilli (11). TST response in our
clinic is evaluated according to the recommendations of
the American Academy of Pediatrics, the US Centers for
Disease Control and Prevention, the American Thoracic
Society, and the Infectious Disease Society of America. TST
induration of ≥5 mm is accepted as positive in children
with a history of close contact with a known or suspected
contagious TB patient, children suspected to have TB,
those receiving immunosuppressive therapy, or those with
immunosuppressive diseases. Induration of ≥10 mm is
considered as positive in children with increased risk of
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disseminated disease younger than 4 years of age or with
chronic diseases/malignancy, or in children with increased
exposure to TB. Induration of ≥15 mm is accepted as
positive in children 4 years of age or older without any risk
factors.
The TST is a routinely used test to screen latent
tuberculosis in our JIA patients on biologic drugs. In our
study, the diameter of induration was measured 48–72 h
after injection by the same investigators (MK and ÖK). We
evaluated TST results of the patients and controls in light
of their BCG vaccination history. We compared our results
with a previous historical JIA cohort on disease-modifying
antirheumatic drug therapy to delineate the additional
role of biologic drugs on the TST response other than the
disease itself. The subjects with an induration equal to or
larger than 5 mm were further evaluated by chest X-ray and
QuantiFERON (QTF). The local ethics committee approved
this study.
2.3. Statistical analysis
The statistical analysis was performed using IBM
SPSS Statistics 21.0 (IBM Corp., Armonk, NY, USA).
Distributional properties of continuous variables were
expressed in terms of mean ± standard deviation and
median (min–max: minimum–maximum). Categorical
variables were presented with frequency and percentage
(%). The Mann–Whitney U and chi-square tests were
used to determine the differences between continuous and
categorical variables of the two groups. Since the design of
the study was mainly based on the diameter of indurations,
the TST variable was considered as the dependent variable
of the study. According to the Shapiro–Wilk test, the TST
result was a nonnormally distributed variable. The subjects
were grouped into two categories according to whether the
TST result was ³5 mm or <5 mm. The risk of the age variable
that could result in a TST induration equal to or more than
5 mm was calculated. Since the mean ages of patients and
healthy subjects were not similar, binary logistic regression
analysis was used to adjust the groups for age (P = 0.072,
Exp(B): 1.052, 95% CI for EXP(B) = 0.995–1.1129). As
a result, we found that the age variable did not have any
risk for TST results of >5 mm. Statistical significance was
obtained at P ≤ 0.05.
3. Results
3.1. Demographic features
Of the 234 JIA patients on biologic drug therapy, 102
(43.6%) were male and 132 (56.4%) were female. Mean
ages of the patients and control group were 12.8 ± 4.7
years (3.2–19.8) and 8.1 ± 3.3 years (2.8–16), respectively.
The mean duration of disease was 5.9 ± 4.1 years (range: 6
months to 17 years). Mean duration of biologic treatment
was 2.5 ± 1.9 years, with a median of 2 years (IQR: 1–3.5).
All demographic characteristics are summarized in Table 1.
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Table 1. Demographic characteristics of the patients.
Patients

Parameters

Mean age of JIA group, mean ± SD (years)
Mean age of control group, mean ± SD (years)

12.7 ± 4.7
8.1 ± 3.3

JIA subtypes
Oligoarticular, n (%)
Polyarticular, n (%)
Systemic, n (%)
Enthesitis-related arthritis, n (%)
Juvenile psoriatic arthritis, n (%)

66 (28)
101 (42.8)
26 (11)
37 (15.7)
4 (1.7)

Duration of disease, mean ± SD (years)

5.8 ± 4.1

Duration of methotrexate treatment, mean ± SD (years)

5.5 ± 4.3

Duration of steroid treatment, mean ± SD (years)

5.6 ± 4.5

Duration of anti-TNF drug treatment, mean ± SD (years)

2.5 ± 1.9

Type of anti-TNF drug
Etanercept, n (%)
Adalimumab, n (%)
Infliximab, n (%)

188 (80.4)
23 (9.8)
23 (9.8)

Presence of TB in the family

22 (9,4)

History of contact with TB

6 (2.6)

Presence of isoniazid prophylaxis

28 (12)

JIA: Juvenile idiopathic arthritis, TB: tuberculosis, anti-TNF: tumor necrosis
factor inhibitors.

3.2. Tuberculin skin test response
The mean diameter of TST induration was 4.9 ± 6.8 mm
(IQR: 0–10 mm) in JIA patients and 7.8 ± 3.5 mm (IQR:
0–16 mm) in controls (P < 0.05). While only 96/234 (41%)
of JIA patients had a TST induration equal to or more than
5 mm, 38/45 (84.4%) of the controls had an induration
of ≥5 mm (P < 0.001). Fifty-nine patients (25.2%) and 19
controls (42.2%) had a TST induration of ≥10 mm (P <
0.05). The TST was nonreactive in 125 (53.4%) and 3 (6.6%)
of the subjects in the JIA and control groups, respectively (P
< 0.001) (Table 2).
3.3. BCG vaccination status
Of the 234 JIA patients, the BCG vaccination history was
negative for 20 of them (6.5%). The mean size of induration
was 2.7 ± 4.7 mm (IQR: 0–5) in this group and this response
was significantly lower than in all of the JIA patients and
healthy controls. The BCG vaccination history was positive
in the rest of the JIA patients and control group. TST
responses were compared regarding the number of BCG
vaccinations between the control and the patient group after
the exclusion of subjects with no history of vaccination. The
mean TST induration was 5.0 ± 6.4 mm (IQR: 0–9) in 149
patients (63.7%) and 7.1 ± 3.2 mm in healthy subjects who
had only been vaccinated once (P > 0.05). In the subjects who

had been vaccinated twice, the mean TST induration was
6.1 ± 8.03 mm (IQR: 0–10) in 65 (27.8%) of the JIA patients
and 10.04 ± 4.1 mm in the control group (P = 0.05) (Table
3). Patients and healthy subjects were categorized according
to their BCG vaccination status and then the two groups
were compared with each other in terms of TST positivity
(TST ≥5 mm). While 63/149 (42.2%) patients who had only
one BCG vaccination in their history had TST positivity,
23/28 (82.1%) healthy controls had positivity (P < 0.001). In
the subjects who had 2 BCG vaccinations in their history,
30 of 65 (46.1%) patients and 15 of 17 (88.2%) controls had
TST positivity (≥5 mm) (P < 0.001). The two groups were
also compared regarding TST induration of ≥10 mm. There
were no significant differences between the JIA patients and
the controls in TST positivity (≥10 mm) among those with
a single BCG vaccine (n = 35/149, 23.5% versus n = 8/28,
28.5%; P = 0.7) and those with 2 BCG vaccines (n = 23/65,
35.4% versus n = 11/17, 64.7%; P > 0.05).
3.4. Anti-TNF therapy and TST response
A total of 188 (80.4%) JIA patients were treated with
etanercept, 23 (9.8%) with adalimumab, and 23 (9.8%)
with infliximab. The mean durations of treatment with
etanercept, adalimumab, and infliximab were 2.6 ± 1.8
years, 2.4 ± 1.2 years, and 3.7 ± 2.7 years, respectively.
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Table 2. Comparison of tuberculin skin test values in study groups.
Juvenile idiopathic
arthritis (n: 234)

Control group
(n: 45)

P

TST induration mm,
mean ± SD

4.99 ± 6.84 mm

7.83 ± 3.47 mm

P < 0.05

TST induration
0–4 mm

138 (59%)

7 (15.5%)

P < 0.001

≥5 mm

37 (15.8%)

38 (84.4%)

P < 0.001

≥10 mm

59 (25.2%)

20 (44.5%)

P < 0.05

TST: Tuberculin skin test.

Table 3. Average tuberculin skin test width and positivity comparison according to the vaccination status.
Juvenile idiopathic
arthritis(n: 234)

Control group
(n: 45)

Vaccination status (No
vaccination in JIA group, n = 20)

BCG = 1
149 (63.7%)

BCG >1
65 (27.8%)

BCG = 1
28 (62.2%)

BCG > 1
17 (37.8%)

TST induration,
mm, mean ± SD

5 ± 6.4

6.1 ± 8.03

7.1 ± 3.2

63(42.2%)
35(23.5%)

30(46.1%)
23(35.4%)

23(82.1%)
8 (28.5%)

TST induration
≥5 mm
≥10 mm

P1

P2

10.04 ± 4.1

P > 0.05

P = 0.05

15 (88.2%)
11(64.7%)

P < 0.001
P > 0.05

P < 0.001
P > 0.05

TST: Tuberculin skin test, JIA: juvenile idiopathic arthritis, BCG: Bacillus Calmette–Guérin, P1: between JIA patients and healthy
children who were vaccinated once, P2: between JIA patients and healthy children who were vaccinated >1 time.

The diameter of the TST induration was measured
among the subjects using various biologic agents. The mean
diameter of the TST induration was smaller in subjects
using etanercept (4.6 ± 6.3 mm, P < 0.05) and adalimumab
(4.9 ± 9.1 mm, P > 0.05) compared to the control group.
However, there was no statistically significant difference
between the patients using infliximab and the control
group (8.3 ± 7.7 mm versus 7.8 ± 3.5 mm, P > 0.05).
The etanercept group did not differ from adalimumab
according to the diameter of the induration. The diameter
of the TST induration was significantly larger in subjects
using infliximab than the other biologic agents (P < 0.001).
3.5. Outcome
In our study, among 96 subjects with a TST induration
of ≥5 mm, 28 patients (29.2 %) had a history of exposure
to TB infection or a positive QTF test. Prophylactic INH
treatment for 9 months was administered to these patients
due to latent TB infection. Among 234 patients, active TB
was detected in only one patient who had a history of close
contact with a school friend with active tuberculosis.
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4. Discussion
In this study, the TST responses of patients treated with
biologic therapy were obtained from their medical
records. Th1 lymphocytes play an important role both in
the disease pathogenesis and in the reaction process of
TST. Since anti-TNF agents inhibit this pathway, they are
used in the treatment of JIA.
Anti-TNF agents seem safe in patients with JIA
according to the majority of published studies. In two
studies from Turkey and Brazil, where TB is common,
none of the patients on anti-TNF treatment developed
clinical or radiological active TB (12,13). Among the
144 JIA patients treated with anti-TNF, only one patient
received anti-TB treatment due to QTF positivity (12).
Similarly, only 3 of 69 JIA patients had TST of ≥5 mm in
a recent study. Consequently, isoniazid prophylaxis was
initiated in those 3 patients and none of them developed
active TB during the follow-up (13).
In 112 adult patients with rheumatoid arthritis (RA),
TST was statistically smaller than in the controls (4.5 mm
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versus 11.5 mm) (6). Moreover, studies among adults
reported that TST response is also poorer in RA patients
receiving anti-TNF treatment (14). Similarly, both the
mean diameter of TST induration and the percentage
of TST positivity are shown to be significantly lower in
patients treated with biologic drugs in our study. The TST
response in the biologic-naive JIA patients was assessed
for the first time in a previous study conducted by our
group. According to this study, neither the activity of the
disease nor the use of corticosteroids and methotrexate
affect the TST response (8). It remains unclear whether
the decreased TST response is related to the disease itself
or biologic agents. Hence, we have compared our current
results with the previous biologic-naive historical cohort
(8). The diameter of the TST response and the frequency
of TST positivity (³5 mm) were not statistically different
between our JIA patients using anti-TNF agents and the
biologic-naive JIA patients of our previous cohort (4.9
mm versus 4.12 mm and 41% versus 39.1%, respectively,
P > 0.05). However, the frequency of unresponsiveness
in the TST was significantly higher in the biologic drugusing JIA patients compared to biologic-naive JIA patients
and the healthy controls (53.4% versus 24.3% and 6.6%,
respectively).
In another study from Turkey, agreement between TST
response and the QTF test was evaluated among 39 JIA
patients and 40 healthy controls. The median induration
of the TST in the JIA patients was significantly smaller
than in the control group (5.8 mm versus 10 mm). Since
all of the QTF-positive patients (n = 2) were TST-negative,
they found no agreement between the QTF and TST. In
conclusion, a single TST test was shown to be incompetent
to detect latent TB (9). There are some controversial results
regarding the effect of JIA activity on TST response (6,8,9).
While Kiray et al. (8) did not find any association between
disease activity and the TST response, in another study
93% of the patients who were unresponsive to the TST had
active disease (9).
In Turkey, the BCG vaccination is given according to
the recommendation of the Turkish Ministry of Health.
While a two-dose vaccination was performed in the
past, only one dose at the end of the second postnatal
month is given according to the current legislation. TST
response is more prominent in patients who underwent
BCG vaccination (15). In our study, the diameter of the
induration was larger in patients with a BCG vaccination
history. In addition, two doses of the vaccination led to
a larger TST response than one dose, similar to the data
from literature (8).

While only 6.6% (n = 3/45) of the healthy subjects
and 24.3% (n = 28/115) of biologic-naive JIA patients were
unresponsive to TST, more than half of our JIA patients (n =
125/234, 53.4%) showed no reaction. It is well understood
that anti-TNF agents not only decrease the TST response
but also completely prevent the TST reaction in more than
half of patients. The unresponsiveness did not differ across
the various anti-TNF agents. These results seem consistent
with previous studies. The frequency of the lack of any
reaction to the TST ranges from 24.3% to 65% among
different studies (6,8,9).
Nonreactive or poor TST results were considered to be
secondary to the disease activity and treatment in patients
with RA (6). In our previous study, TST reaction was not
observed in 24.3% of the biologic-naive JIA patients (8).
However, in the current study the frequency of subjects
with no reaction was found to be increased (53.4%). The
disease itself causes a decline in the TST response. AntiTNF agents also seem to further decrease and hinder the
TST response in patients with JIA.
The major limitations of our study are the absence of
biologic-naive JIA patients and its retrospective nature.
However, we were able to compare the TST results of
current anti-TNF-using JIA patients with the biologicnaive JIA patients of our previous study (8). Another
limitation is the lack of correlation of the disease activity
with TST response. We could not find any association
between disease activity and TST induration previously
(8). Since recruitment of a new control group to the study
posed some ethical concerns, we used the same control
group of our previous study. Hence, the mean age of the
control and study group did not match.
Formerly, we demonstrated the decreased TST
response in biologic-naive JIA patients. In this study, the
TST response was found to be decreased in the JIA patients
on anti-TNF agents compared to the controls. Although
there was no difference between the JIA patients with and
without use of biologic agents in terms of the mean TST
response, the frequency of unresponsive patients among
the JIA patients on biologic agents was substantially higher
compared to the biologic-naive JIA patients and healthy
controls.
In conclusion, TST alone seems inadequate to recognize
latent TB both in biologic-naive JIA patients and in JIA
patients on anti-TNF therapy. Further prospective studies
evaluating the TST responses sequentially in JIA patients
on anti-TNF treatment would provide better results about
the effect of biologic drugs on the TST response.
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